Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma

BMC Genomics

Volumn 16, Issue 1, 2015, Pages

  Espinal Enríquez, Jesús ^a,b   Muñoz Montero, Said ^a   Imaz Rosshandler, Ivan ^a   Huerta Verde, Aldo ^a   Mejía, Carmen ^c   Hernández Lemus, Enrique ^a,b  

^a INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE QUERÉTARO   (Mexico)

Author keywords

Anaplastic thyroid cancer; Genome wide analysis; Inhibition of matrix metalloproteinases; Pathway analysis; Thyroid carcinoma progression

Indexed keywords

HERMES ANTIGEN; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; PENTRAXIN 3; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN BAX; PROTEIN C JUN; PROTEIN KINASE B; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR FKHR; BIOLOGICAL MARKER;

APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL INTERACTION; CELL SURVIVAL; COLEC12 GENE; CONTROLLED STUDY; DEPDC1 GENE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; DNA REPAIR; DOWN REGULATION; ENZYME INHIBITION; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GPR110 GENE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; METASTASIS; MITOSIS; MMP1 GENE; MMP3 GENE; MOLECULAR INTERACTION; NUSAP1 GENE; PDGFRA GENE; PHENOTYPE; PLAU GENE; PLAUR GENE; PTX3 GENE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPP1 GENE; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; TIMP3 GENE; TUMOR INVASION; UNDIFFERENTIATED CARCINOMA; UNDIFFERENTIATED THYROID CARCINOMA; UPREGULATION; VALIDATION PROCESS; BIOLOGY; CANCER GRADING; CELL COMMUNICATION; GENETIC DATABASE; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; REPRODUCIBILITY; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

BIOMARKERS; CELL COMMUNICATION; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR SEQUENCE ANNOTATION; NEOPLASM GRADING; REPRODUCIBILITY OF RESULTS; ROC CURVE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84925660402     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-015-1372-0     Document Type: Article

References (58)

1. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007; 8(2):148-56.
2. Braunstein GD, Sacks W. Thyroid Cancer: Springer US; 2012. doi:10.1007/978-1-4614-0875-8. http://link.springer.com/book/10.1007%2F978-1-4614-0875-8.
3. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988; 48(16):4459-63.
4. LiVolsi VA, Baloch ZW. Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol. 2004; 11(6):279-87.
5. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006; 94(8):662-9. doi:10.1002/jso.20700.
6. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. Ras point mutations and pax8-ppar gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003; 88(5):2318-26. doi:10.1210/jc.2002-021907.
7. Eberhardt NL, Grebe SKG, McIver B, Reddi HV. The role of the pax8/ppargamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol. 2010; 321(1):50-6. doi:10.1016/j.mce.2009.10.013.
8. Hou P, Ji M, Xing M. Association of pten gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/akt signaling pathway in thyroid tumors. Cancer. 2008; 113(9):2440-47. doi:10.1002/cncr.23869.
9. Ain KB. Papillary thyroid carcinoma. etiology, assessment, and therapy. Endocrinol Metab Clin North Am. 1995; 24(4):711-60.
10. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998; 338(5):297-306. doi:10.1056/NEJM199801293380506.
11. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and braf mutation in papillary thyroid cancer. Int J Cancer. 2006; 119(10):2322-29. doi:10.1002/ijc.22110.
12. Basolo F, Caligo MA, Pinchera A, Fedeli F, Baldanzi A, Miccoli P, et al. Cyclin d1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and ki67 labeling index. Thyroid. 2000; 10(9):741-6.
13. van Weering DH, Bos JL. Signal transduction by the receptor tyrosine kinase ret. Recent Results Cancer Res. 1998; 154:271-81.
14. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. a clinicopathologic study of 121 cases. Cancer. 1990; 66(2):321-30.
15. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJA, et al. Mutation of the pik3ca gene in anaplastic thyroid cancer. Cancer Res. 2005; 65(22):10199-207. doi:10.1158/0008-5472.CAN-04-4259.
16. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of braf gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003; 63(15):4561-7.
17. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M, et al. Ras mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009; 94(12):4735-41. doi:10.1210/jc.2009-1233.
18. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (frma). Biostatistics. 2010; 11(2):242-53. doi:10.1093/biostatistics/kxp059.
19. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:3. doi:10.2202/1544-6115.1027.
20. Smyth GK. limma: Linear models for microarray data. Bioinf Comput Biol Solutions Using R Bioconductor. 2005:397-420.
21. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim J-S, et al. A novel signaling pathway impact analysis. Bioinformatics. 2009; 25(1):75-82. doi:10.1093/bioinformatics/btn577.
22. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using paradigm. Bioinformatics. 2010; 26(12):237-45. doi:10.1093/bioinformatics/btq182.
23. Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of cancer. Proc Natl Acad Sci USA. 2013; 110(16):6388-93. doi:10.1073/pnas.1219651110.
24. Huang S, Yee C, Ching T, Yu H, Garmire LX. A novel model to combine clinical and pathway-based transcriptomic information for the prognosis prediction of breast cancer. PLoS Comput Biol. 2014; 10(9):1003851. doi:10.1371/journal.pcbi.1003851.
25. Verhaegh W, van Ooijen H, Inda MA, Hatzis P, Versteeg R, Smid M, et al. Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. Cancer Res. 2014; 74(11):2936-45. doi:10.1158/0008-5472.CAN-13-2515.
26. Wang J, Duncan D, Shi Z, Zhang B. Web-based gene set analysis toolkit (webgestalt): update 2013. Nucleic Acids Res. 2013; 41(Web Server issue):77-83. doi:10.1093/nar/gkt439.
27. Krämer A, Green J, Pollard Jr J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014; 30(4):523-30. doi:10.1093/bioinformatics/btt703.
28. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al.Discovery and prioritization of somatic mutations in diffuse large b-cell lymphoma (dlbcl) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012; 109(10):3879-84. doi:10.1073/pnas.1121343109.
29. Chindelevitch L, Ziemek D, Enayetallah A, Randhawa R, Sidders B, Brockel C, et al. Causal reasoning on biological networks: interpreting transcriptional changes. Bioinformatics. 2012; 28(8):1114-21. doi:10.1093/bioinformatics/bts090.
30. Chindelevitch L, Loh P-R, Enayetallah A, Berger B, Ziemek D. Assessing statistical significance in causal graphs. BMC Bioinf. 2012; 13:35. doi:10.1186/1471-2105-13-35.
31. Espinosa AM, Alfaro A, Roman-Basaure E, Guardado-Estrada M, ícela P, Serralde C, et al. Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One. 2013; 8(2):55975. doi:10.1371/journal.pone.0055975.
32. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, et al. Involvement of upregulation of depdc1 (dep domain containing 1) in bladder carcinogenesis. Oncogene. 2007; 26(44):6448-55. doi:10.1038/sj.onc.1210466.
33. Kassambara A, Schoenhals M, Moreaux J, Veyrune J-L, Reme T, Goldschmidt H, et al. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One. 2013; 8(4):62752. doi:10.1371/journal.pone.0062752.
34. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463-516. doi:10.1146/annurev.cellbio.17.1.463.
35. Teshima J, Doi H, Fujimori K, Watanabe M, Nakajima N, Nakano T, et al. A human thyroid cancer cell line, dh-14-3, newly established from poorly differentiated thyroid carcinoma. Tohoku J Exp Med. 2013; 230(2):75-82.
36. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999; 274(31):21491-4.
37. DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer. 2000; 36(10):1258-68.
38. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of timp-3. Br J Cancer. 1999; 79(9-10):1347-55. doi:10.1038/sj.bjc.6690217.
39. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, et al. Timp-2 over-expression reduces invasion and angiogenesis and protects b16f10 melanoma cells from apoptosis. Int J Cancer. 1998; 75(2):246-53.
40. Iruela-Arispe ML, Carpizo D, Luque A. Adamts1: a matrix metalloprotease with angioinhibitory properties. Ann N Y Acad Sci. 2003; 995:183-90.
41. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, et al. The membrane-anchored mmp inhibitor reck is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001; 107(6):789-800.
42. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010; 103(6):861-9. doi:10.1038/sj.bjc.6605834.
43. Briese J, Cheng S, Ezzat S, Liu W, Winer D, Wagener C, et al. Osteopontin (opn) expression in thyroid carcinoma. Anticancer Res. 2010; 30(5):1681-8.
44. Oler G, Camacho CP, Hojaij FC, Michaluart P, Riggins GJ, Cerutti JM. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with braf mutational status and lymph node metastasis. Clin Cancer Res. 2008; 14(15):4735-42. doi:10.1158/1078-0432.CCR-07-4372.
45. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, Falco VD, et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab. 2005; 90(9):5270-8. doi:10.1210/jc.2005-0271.
46. Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, et al. In papillary thyroid carcinoma brafv600e is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol (Oxf). 2012; 77(5):780-6. doi:10.1111/j.1365-2265.2012.04465.x.
47. Ulisse S, Baldini E, Sorrenti S, Barollo S, Gnessi L, Catania A, et al. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2011; 96(2):504-8. doi:10.1210/jc.2010-1688.
48. Sid B, Dedieu S, Delorme N, Sartelet H, Rath GM, Bellon G, et al. Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator. Int J Biochem Cell Biol. 2006; 38(10):1729-40. doi:10.1016/j.biocel.2006.04.005.
49. Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol. 2008; 15(10):2811-26. doi:10.1245/s10434-008-0034-8.
50. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, et al. Upregulation of hmga2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer. 2008; 47(1):56-63. doi:10.1002/gcc.20505.
51. Chiappetta G, Botti G, Monaco M, Pasquinelli R, Pentimalli F, Bonito MD, et al. Hmga1 protein overexpression in human breast carcinomas: correlation with erbb2 expression. Clin Cancer Res. 2004; 10(22):7637-44. doi:10.1158/1078-0432.CCR-04-0291.
52. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, et al. A phase ii study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010; 20(9):975-80. doi:10.1089/thy.2010.0057.
53. Zhang J, Wang P, Dykstra M, Gelebart P, Williams D, Ingham R, et al. Platelet-derived growth factor receptor- α promotes lymphatic metastases in papillary thyroid cancer. J Pathol. 2012; 228(2):241-50. doi:10.1002/path.4069.
54. Che H-Y, Guo H-Y, Si X-W, You Q-Y, Lou W-Y. Additive effect by combination of akt inhibitor, mk-2206, and pdgfr inhibitor, tyrphostin ag 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility. Onco Targets Ther. 2014; 7:425-32. doi:10.2147/OTT.S57324.
55. Chen K-T, Lin J-D, Liou M-J, Weng H-F, Chang CA, Chan E-C. An aberrant autocrine activation of the platelet-derived growth factor alpha-receptor in follicular and papillary thyroid carcinoma cell lines. Cancer Lett. 2006; 231(2):192-205. doi:10.1016/j.canlet.2005.01.039.
56. Lum AM, Wang BB, Beck-Engeser GB, Li L, Channa N, Wabl M. Orphan receptor gpr110, an oncogene overexpressed in lung and prostate cancer. BMC Cancer. 2010; 10:40. doi:10.1186/1471-2407-10-40.
57. Zhang D, Ren W-H, Gao Y, Wang N-Y, Wu W-J. Clinical significance and prognostic value of pentraxin-3 as serologic biomarker for lung cancer. Asian Pac J Cancer Prev. 2013; 14(7):4215-21.
58. Tosi F, Sarra DD, Bonin C, Zambotti F, Dall'Alda M, Fiers T, et al. Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome. Eur J Endocrinol. 2014; 170(3):401-9. doi:10.1530/EJE-13-0761.